Hit and Miss in Castration-Resistant Prostate Cancer

(MedPage Today) -- An extended progression-free interval failed to translate into better overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) treated with two androgen-targeted drugs instead of one, a randomized trial...